Tubeimoside-1, a PD-L1 inhibitor, selectively binds to the mTOR kinase target and inhibits the activation of mTORC1, which results in TFEB nuclear translocation and induction of lysosomal biogenesis as well as reduces the abundance of PD-L1 to enhance the cytotoxicity of T cells against tuomr cells, thereby playing an anti-tumor role (Liu X. et al., 2021). The gene discussed is CD274; the disease is neoplasm.